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Abstract
Background: Depression guidelines in the UK recommended a policy of watchful waiting for mild
depression due to a lack of evidence for the effectiveness of antidepressant treatment for mild
cases. However there has been relatively little research carried out in primary care to help establish
the severity threshold at which antidepressant treatment is effective and cost-effective.
Methods/Design:  The THREAD (THREshold for AntiDepressants) study is a multi-centre
randomised controlled trial designed to determine the clinical and cost effectiveness of a selective
serotonin reuptake inhibitor (SSRI) plus general practitioner (GP) supportive care, versus
supportive care alone, for mild to moderate depression in primary care. The aim is to recruit 300
patients from three centres (Southampton, London and Liverpool). Depressive symptoms will be
assessed at baseline, 12 weeks and 26 weeks, using the 17-item Hamilton Depression Rating Scale
(HDRS). Two severity sub-groups of patients will be recruited, with HDRS scores of 12–15, and
16–19. Possible predictors of response will be explored including life events and difficulties and
alcohol consumption. Analysis of covariance, controlling for baseline value, severity group and
centre will be used to estimate the overall treatment effectiveness (difference in HDRS score) at
final follow up. The primary analysis will be by 'intention to treat' using double sided tests. The
interaction between severity sub-group and treatment will be tested, and if appropriate, effects
within separate severity sub-groups estimated. The economic analysis will compare the two
treatment groups in terms of mean costs and cost-effectiveness.
Discussion: The results of this study will give GPs important information to help them determine
the severity of depression at which antidepressant treatment is likely to be cost-effective.
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Background
Increasing prescribing of antidepressants – is it 
appropriate?
Prescribing of antidepressant drugs has increased by 36%
over the last 5 years to around 30 million items (7.3 mil-
lion in the quarter to June 2005), and the cost has
increased by 20% to around £380 million (£91 million
for the same quarter) [1].
However, much of this increased prescribing may be inap-
propriate. As a result of the perceived pressure to treat
more depression, antidepressants are being prescribed
more frequently for depressive symptoms below the
threshold for major depression [2]. Clinical guidelines
recommend antidepressant medication as first-line treat-
ment for patients meeting diagnostic criteria for major
depressive disorder [3,4]. Antidepressants are not recom-
mended for the initial treatment of mild depression
because the risk-benefit ratio is considered to be poor.
However, these guidelines have been produced based
largely on consensus or expert opinion. There has been
relatively little research in primary care on which to base
recommendations on the threshold at which antidepres-
sants should be offered. Studies in primary care have
shown that antidepressants are more effective than pla-
cebo or treatment as usual for probable major depression
but results have been mixed for minor (mild) depression.
Previous research in primary care
A general practice based placebo-controlled trial of
amitriptyline found that patients with probable major
depressive disorder benefited from drug treatment, but
those with minor depression did no better on them than
on placebo [5]. However these findings represent a post-
hoc analysis of responses in the two sub-groups of
patients who did or did not fulfil criteria for a diagnosis of
probable major depression. The study was not set up spe-
cifically to assess the relationship between severity and
response to treatment.
A placebo-controlled trial of the SSRI paroxetine, versus
problem-solving, versus non-specific clinical manage-
ment or 'watchful waiting' for minor depression and dys-
thymia in a primary care population was undertaken in
the USA [6]. The results were mixed: among patients aged
18 to 59 years with dysthymia, paroxetine improved
remission compared with placebo plus non-specific clini-
cal management, while for minor depression they were
equally effective [7]. Among patients aged 60 and over
paroxetine was beneficial in dysthymia and among more
severely impaired patients with minor depression [8]. The
authors suggested that 'watchful waiting' i.e. supportive
care but without the prescription of antidepressants, was
an appropriate treatment option for minor depression, at
least in adults and in elderly patients with mild impair-
ment.
Judd et al [9] carried out a randomised placebo controlled
trial of fluoxetine among 162 patients with minor depres-
sive disorder and found that fluoxetine was better in terms
of clinical effectiveness in terms of the Hamilton Depres-
sion Rating Scale (HDRS). The mean difference was only
one point on the HDRS. Minor depression in these sub-
jects was primarily characterised by mood and cognitive
symptoms, not the classical neurovegetative signs and
symptoms. One third had a past history of major depres-
sive disorder, however HDRS scores at baseline ranged
from 6–21 inclusive, on the 17 item scale [10].
Finally, most recently, Perahia et al [11] found that
duloxetine was more effective than placebo in 159
patients with milder major depressive disorder (HDRS
scores on the HAMD17 between 15 and 18 inclusive) over
9 weeks. The mean different was relatively small, 2.9
points on the HDRS. However, this was a post-hoc sub-
group analysis of pooled data from two trials.
There is evidence that one form of mild depression, dys-
thymia, responds to antidepressants. Dysthymia is a term
used to describe chronic low-grade depression and in
ICD-10 requires that four or more depressive symptoms
are present for at least two years [12]. A recent systematic
review and meta-analysis suggested that antidepressant
drug treatment is effective in the management of dys-
thymia, but the research studies analysed were conducted
in secondary care settings [13].
Predictors of response
The placebo-controlled trial of amitriptyline in general
practice referred to above found no difference between
those categorised as having endogenous and non-endog-
enous depression. The authors recommended drug treat-
ment for major depression, regardless of demographic
characteristics, a past history of depression, or the pres-
ence or absence of endogenous features [14]. These find-
ings have led to recommendations to prescribe drug
treatment for depression if symptoms are severe enough,
and functioning is impaired, even if there seems to be an
understandable cause for depression such as adverse
events or continuing difficulties in the patient's life [3,15-
17]. However, the importance of social factors in depres-
sion is undeniable, and there is substantial evidence to
suggest that both onset and recovery are related to life
events and difficulties.
Depression is strongly associated with lower socioeco-
nomic status [18,19], poverty [20], unemployment
[19,21], separation or divorce [18,22], and poor housing
[23]. Predisposing factors among women includeBMC Family Practice 2007, 8:2 http://www.biomedcentral.com/1471-2296/8/2
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demanding child care [24], lone motherhood and poor
social support [25]. A lower severity of premorbid difficul-
ties has been shown to be associated with a reduced time
to remission, at least among patients with high self-
esteem and better coping strategies [26]. Recovery from
depression is related to positive social support and life
events which can be perceived as 'fresh starts', which may
or may not be related to the original adverse events and
difficulties associated with onset [27]. A reduction in
marked social difficulties has been found to predict recov-
ery from depression among patients in primary care [28]
whereas recognition and drug treatment by the general
practitioner has not [29,30].
The scant research into psychosocial predictors of
response carried out so far in secondary care suggests that
greater emotional support, and a relative lack of experi-
ence of adversity, particularly in domains of the patient's
life which are regarded as most important, are more
strongly related to recovery than drug treatment [31]. As
findings in secondary care may not generalise to primary
care however, more research is needed to determine
whether such social and cognitive factors predict response
to drug treatment in a primary care setting.
In general somatic presentations of depressive disorder
are associated with reduced severity of depressive symp-
toms but similar impairments in function and a similar
prognosis [32]. However, it is important to go on to
explore whether the number of physical symptoms affects
treatment responses when comparing drug and non-drug
treatments.
The need for a new study
The US studies described above compared SSRIs to pla-
cebo and were therefore efficacy trials which cannot estab-
lish cost-effectiveness in practice. Also, findings from the
USA may not generalise to primary care in the UK, as the
type of supportive care usually provided in the UK, which
may include referral to a practice counsellor, differs from
the 'watchful waiting' provided in the US study. If SSRI
treatment is effective in mild depression, its cost-effective-
ness needs to be established within the UK health care sys-
tem. Predictors of response to antidepressant treatment
also need to be identified, to help practitioners decide
which patients should be offered them.
The THREAD study is designed to inform guideline rec-
ommendations by exploring in general practice whether
the added prescription of a SSRI antidepressant is more
cost-effective than support from the GP alone in patients
with mild to moderate depression.
Our research questions are:
1. Is treatment with a SSRI plus supportive care more
effective and cost-effective than supportive care alone?
2. If it is more effective, does this apply across the whole
range of severity of symptoms of mild to moderate depres-
sion?
3. What patient factors might predict a beneficial
response?
The hypothesis is that SSRI treatment will be more effec-
tive and cost-effective than supportive care alone among
patients scoring 16–19 on the Hamilton Rating Scale
(HDRS) but not among those scoring 12–15.
We will also explore the impact of a number of predictors
on the outcome in the two treatment arms, namely demo-
graphic and social variables, alcohol consumption, physi-
cal symptoms, recent life events and difficulties, the
patient's self-rating of the cause of their illness, and the
duration of their depressive symptoms.
Methods/Design
Trial design
The study is a randomised controlled trial that compares
treatment with a SSRI plus supportive care, versus sup-
portive care alone, over 26 weeks follow-up. The aim is to
establish the clinical and cost effectiveness of SSRI antide-
pressants added to GP support over GP support alone, in
clinical practice conditions. It is not an efficacy study and
there is no placebo control group (placebos are not given
in clinical practice and cannot be costed into the eco-
nomic analysis).
Ethical approval
Ethical approval was gained from the West Midlands
Multi-Centre Research Committee (MREC) (reference
number: 02/7/091).
Setting
Patients are being recruited from general practices around
three centres: Southampton, London (co-ordinated by the




Patients are eligible for inclusion if they are aged 18 and
above, and are found to be depressed by their GPs and
potentially in need of treatment. Patients must have at
least one somatic symptom on the Bradford Somatic
Inventory [33]. Only patients for whom the likely benefit
of treatment is uncertain in the mind of the GP are
referred to the study because it is essential that the GP is
in equipoise about the likely outcome. To avoid includingBMC Family Practice 2007, 8:2 http://www.biomedcentral.com/1471-2296/8/2
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patients with more transient depression, they need to
have had symptoms for at least eight weeks. To include
only patients with new episodes of depression, they must
not have received treatment for depression within the pre-
vious 12 months.
Exclusion criteria
Patients are excluded from the study if:
• they are found to have an HDRS score of less than 12, or
greater than 19
• they suffer from suicidal intent
• they report significant substance misuse, determined
using screening questions
• if they score 13 or more on the Alcohol Use Disorders
Identification Test (AUDIT) questionnaire
• they do not have the spoken or written language skills
necessary to take part
Figure 1 shows the procedure of what is involved for the
patients recruited into the study.
Interventions
Supportive care alone
The GP is asked to see the patient for support in follow-up
appointments at 2, 4, 8 and 12 weeks after they have been
randomised into the study. They are asked to refrain from
prescribing antidepressants during this 12 week period.
However, if the patient deteriorates and the GP feels that
they are in need of antidepressants then they can be
started on drug treatment. If this does occur then the
patient can continue in the study but remains in the sup-
port alone arm on an intention to treat basis.
SSRI antidepressant plus supportive care
The patient is prescribed an appropriate SSRI and then
seen by the GP at the times listed above. The GP is also at
liberty to switch SSRIs should the initial choice prove
unsuitable. The GP is advised to continue treatment for
four months after recovery but it is stressed to the GP that
this is a pragmatic study and that they should use their
clinical judgement in relation to the duration of the
patient's treatment.
The GPs are free to refer patients in either arm for counsel-
ling or psychological therapy if this is appropriate in their
judgement, but waiting times for counselling and psycho-
logical treatment are such that patients will not usually
receive this before the 12 week follow-up, and so this will
not affect the comparison for the primary outcome.
Randomisation
Block randomisation with random block sizes, stratified
by severity sub-group and centre, is carried out by an inde-
pendent centre (The Institute of Psychiatry Clinical Trials
Unit) over the telephone.
Blindness
The researchers carrying out the interviews are kept blind
to the treatment arm, if possible. Patients are asked not to
reveal whether or not they have been prescribed antide-
pressants prior to the follow-up interviews. All instances
of unblinding are recorded.
Patient assessments
The initial assessment takes place at baseline with follow
up interviews being carried out at 12 and 26 weeks after
randomisation. Table 1 summarizes the measures that are
used at each point.
Outcome measures
The primary outcome measure is the 17-item HDRS score
at 12 weeks. The BDI-II, the SF-36, the Patient Satisfaction
Scale and the HDRS at 26 weeks are all secondary out-
comes. The sociodemographic, duration of depression,
alcohol consumption, somatic symptom inventory, LEDS
and symptom attribution measures are all potential pre-
dictors of response.
Depressive symptoms
The Hamilton Depression Rating Scale (HDRS) is used to
measure depressive symptoms as the primary outcome. A
large number of studies have shown it to be a valid and
reliable measure of depression [34]. Also it is sensitive to
changes due to drug effects in a general practice setting
[35]. The structured 17-item interview version of the
HDRS is being used in this study and all the researchers
involved have received extensive and on-going training in
this measure [36]. Inter-rater reliability of ratings on the
HDRS is being assessed at intervals throughout the recruit-
ment and follow-up period.
The Beck Depression Inventory second edition (BDI-II) is
a second measure of depressive symptoms [37]. This is a
21-item self-report rating inventory measuring character-
istic attitudes and symptoms of depression. As this is self-
complete it should be essentially free of any observer bias
which will enable a check to be carried out to ensure that
there is no systematic bias in the HDRS ratings arising
from possible un-blinding of the researchers to treatment
arm.
Quality of life
The SF-36 is a questionnaire consisting of 36 items con-
cerning respondents' health-related quality of life [38].
The responses to the items can be condensed into scoresBMC Family Practice 2007, 8:2 http://www.biomedcentral.com/1471-2296/8/2
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Trial design Figure 1
Trial design. Flow chart to show the study procedure.
Patient is identified by GP in routine practice consultations
Patient is contacted and visited by researchers and fully 
informed about study
Consent and baseline assessment is carried out by researcher
Patient is 
randomised by study 
co-ordinator
n = 300
GP supportive care alone
n = 150
SSRI + GP supportive 
care
n = 150
Patient attends GP 
appointments at 2, 4, 8 
and 12 weeks
Patient has follow up 
interview with researcher 
at 12 weeks
Patient has follow up 
interview with researcher 
at 12 weeks
Patient attends GP 
appointments at 2, 4, 8 
and 12 weeks
Patient has follow up 
interview with researcher 
at 26 weeks
Patient has follow up 
interview with researcher 
at 26 weeks
Researcher extracts 
contact and medication 
data from GP surgery
Researcher extracts 
contact and medication 
data from GP surgeryBMC Family Practice 2007, 8:2 http://www.biomedcentral.com/1471-2296/8/2
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on eight domains of health-related quality of life: physical
functioning, role-physical, role-emotional, social func-
tioning, pain vitality, mental health and general health.
The SF-36 will be used to calculate quality-adjusted life
years (QALYs) to be used in the cost-effectiveness or cost
utility analysis.
Short life events and difficulties scale
This instrument is usually used to collect information
about stressful experiences over a one-year period before
onset/relapse of disorder. It differs from many other stress
measures by distinguishing acute from ongoing stressors
(events from difficulties), and by contrasting short and
long term, and contextual and subjective ratings of these
experiences. Specific qualitative aspects of stress such as
losses, dangers, humiliations, entrapments, challenges
and goal frustrations are also deliberately contrasted [39].
The shortened version of the LEDS, used in this study, is
essentially the same interview process but the ratings con-
centrate on those events that are considered severe, with
marked or moderate threat to the individual, and not on
those which are deemed to carry only some or little threat,
unless they are a fresh start experience of the type found to
predict depressive remission.
Alcohol consumption
The Alcohol Use Disorders Identification Test (AUDIT) is
a 10-item questionnaire designed by the World Health
Organisation to screen for hazardous alcohol intake in
primary health care settings. It has high sensitivity and
specificity and can be self-completed or administered in
2–4 minutes [40].
Somatic symptoms
The Bradford Somatic Inventory is a 46 item question-
naire about symptoms experienced in the last month,
which was especially designed to detect physical symp-
toms commonly found in depressed patients [33].
Patient satisfaction
This is a 7-point Likert rating scale to determine the
patient's satisfaction with the care they have been given.
This includes the doctor's explanation of the illness and its
seriousness, whether the doctor told the patient what they
Table 1: Summary of measures
Measure Baseline 12 week follow-up 26 week follow-up
17-item Hamilton Depression Rating Scale Interview (HDRS)
Sociodemographic questionnaire
AUDIT measure of alcohol consumption
Beck Depression Inventory (BDI-II)
Date of onset questionnaire
Short Form 36 (SF36) – health-related quality of life measure
Bradford Somatic Inventory (BSI)
Short Life Events and Difficulties Schedule (S-LEDS)
Symptom attribution questionnaire
Patient expectations questionnaire
Client Service Receipt Inventory (CSRI)
Patient Satisfaction Scale
Measure of Care Received questionnaire
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wanted to know, the doctor's interest in the person,
warmth, friendliness, treatment of the patient as an equal,
understanding, relief of problems relief of worries, and
whether the patient understood how to follow the doc-
tor's advice. This questionnaire was developed by the Pri-
mary Medical Care Group at Southampton.
Care received
This is being measured at 12 and 26 weeks using a self-
report questionnaire that was specifically designed for this
study to provide a measure of the content of the consulta-
tions in order to determine whether supportive care was
comparable in both arms. It includes 4 questions devised
by Morisky et al [41] which are used to measure patient
adherence to the medication for those in the antidepres-
sant treatment arm.
Economic evaluation
Client Service Receipt Inventory
Service use is measured comprehensively using a modi-
fied version of the Client Service Receipt Inventory (CSRI)
[42] at baseline and 26 weeks. This will allow the eco-
nomic impact of the different treatment options to be
ascertained. Services measured include all contacts with
GPs, other primary care professionals, psychiatrists, psy-
chologists, community mental health nurses, counsellors,
social care professionals and complementary therapy.
Analysis of costs
Costs are calculated using data collected through the CSRI
at the 12 and 26 week follow ups. Service use and medica-
tion data which are collected from the surgery records will
be pooled with the CSRI data to maximise completeness.
These will be multiplied by standard unit cost data to gen-
erate service costs for each patient.
Sample size
The sample will be divided into two severity sub-groups
(HDRS scores 12–15 and 16–19). Hollyman et al found
the standard deviation (SD) of the HDRS to be around
3.5, and reported roughly similar numbers of patients in
these two severity ranges [43]. We assume this SD, equal
numbers in the two sub-groups, a pre-post correlation of
0.5, and significance level of 0.05.
Using analysis of covariance controlling for baseline val-
ues, 49 patients at follow-up in each treatment/severity
combination will allow the following effects to be
detected (standard effect sizes in brackets): an overall
average difference in HDRS score of 1.4 (0.4) with 90%
power; an interaction (difference between effects in the
two severity sub-groups) of 2.5 (0.7) with 80% power;
and a difference between treatment arms within the more
severe group of 2.0 (0.6) with 90% power. The latter two
calculations are conservative (tending to underestimate
the power) because the SDs may be lower within the
severity subgroups. A difference of 1.4 on the HDRS is a
relatively small difference (0.4 standard deviations) and
any difference smaller than this we regard as clinically
insignificant. In the trial of amitriptyline by Hollyman et
al the HDRS scores fell by a mean of around 10 points in
the mildly depressed group and around 13 in the more
severely affected group [43]. Therefore the sample size
should be sufficient to detect clinically significant differ-
ences.
One hundred and ninety six patients will therefore need
to be followed up to detect these differences (98 in each
of the two arms). To allow for up to 25% loss to follow-
up at 12 weeks, 261, 87 at each of the three sites, would
be needed. The aim is to recruit 300, 100 at each site.
Analysis
Analysis of covariance, controlling for baseline value,
severity sub-group and centre will be used to estimate the
overall treatment effectiveness (difference in HDRS score)
at follow up. The primary analysis will be by 'intention to
treat' using double sided tests. The interaction between
severity sub-group and treatment will be tested, and if
appropriate, effects within separate severity sub-groups
estimated. Further exploratory analyses will also assess the
impact of other explanatory factors and will also model
the time course of effects using the 12-week measurement
in a panel analysis. Sensitivity analyses will include esti-
mating 'on treatment' effects and CACE (complier average
causal effects), and by imputation of any missing values.
The main aim of the economic analysis is to compare the
two treatment groups in terms of mean costs and cost-
effectiveness. A secondary aim is to examine differences
between the sub-groups defined by severity. Cost data are
frequently skewed and this can cause a violation of the
assumptions of standard significance tests. In the event of
this, bootstrapped estimates (multiple re-sampling within
treatment arms) will be determined, whereby mean costs
can still be compared whilst imposing no prior assump-
tions regarding the data distribution. To explore cost-
effectiveness, a net benefit variable will be generated
which synthesises data on costs and outcomes, also ana-
lysed by bootstrapping.
Discussion
It is intended that this study will provide the evidence
needed to enable GPs to decide which of their patients
suffering from mild and moderate depression are most
likely to benefit from taking an SSRI antidepressant with
regard to severity as well as other predictors.BMC Family Practice 2007, 8:2 http://www.biomedcentral.com/1471-2296/8/2
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